Reichle, Albrecht and Vogt, Thomas and Coras, Brigitte and Terheyden, Peter and Neuber, Klaus and Trefzer, Uwe and Schultz, Erwin and Berand, Anna and Broecker, E. B. and Landthaler, Michael and Andreesen, Reinhard (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. MELANOMA RESEARCH, 17 (6). pp. 360-364. ISSN 0960-8931,
Full text not available from this repository. (Request a copy)Abstract
An angiostatic approach was used to assess the impact of anti-inflammatory therapy in combination with metronomic low-dose chemotherapy. A randomized multi-institutional phase 11 trial was designed to select metronomic chemotherapy (arm A: trofosfamide 50 mg orally three times daily, day 1 +) or combined anti-inflammatory/angiostatic treatment (arm B: trofosfamide as above mentioned plus rofecoxib 25 mg orally, day 1 +, and pioglitazone 60mg orally, day 1 +) for further evaluation. A total of 76 patients, mostly (>60%) refractory to at least one previous chemotherapy with maximum tolerated doses, and progression of metastatic melanoma were included. The estimated progression-free survival (PFS) rates at one year were 0% for metronomic chemotherapy (A), but 9% for additional anti-inflammatory therapy (B). Vice versa the hazard ratio for the intent-to-treat analysis of A versus B was 1.9 (P=0.008). By Cox analysis, the impact of anti-inflammatory therapy on PFS achieved significance (P=0.016) as well as C-reactive protein response on overall survival (P=0.045). WHO grade 3 (no grade 4) toxicities were reported in arm A/B in 19 and 28%, respectively. In conclusion, control of tumour-associated inflammatory processes (C-reactive protein response) is associated with longer PFS than achieved with metronomic chemotherapy alone in metastatic melanoma.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | MALIGNANT-MELANOMA; CANCER; CYCLOOXYGENASE-2; CHEMOTHERAPY; DACARBAZINE; INHIBITOR; advanced melanoma; angiostatic therapy; anti-inflammatory treatment COX-2; C-reactive protein; PPAR gamma |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Dermatologie und Venerologie Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Nov 2020 09:37 |
| Last Modified: | 25 Nov 2020 09:37 |
| URI: | https://pred.uni-regensburg.de/id/eprint/31867 |
Actions (login required)
 |
View Item |
